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Abstract
Background: The Plasmodium falciparum chimeric protein PfCP-2.9 is a promising asexual-stage malaria vaccine
evaluated in clinical trials. This chimeric protein consists of two cysteine-rich domains: domain III of the apical
membrane antigen 1 (AMA-1 [III]) and the C-terminal region of the merozoite surface protein 1 (MSP1-19). It has
been reported that the fusion of these two antigens enhanced their immunogenicity and antibody-mediated
inhibition of parasite growth in vitro.
Methods: The
15N-labeled and
13C/
15N-labeled PfCP-2.9 was produced in Pichia pastoris for nuclear magnetic
resonance (NMR) structure analysis. The chemical shift assignments of PfCP-2.9 were compared with those
previously reported for the individual domains (i.e., PfAMA-1(III) or PfMSP 1-19). The two-dimensional spectra and
transverse relaxation rates (R2) of the PfMSP1-19 alone were compared with that of the PfCP-2.9.
Results: Confident backbone assignments were obtained for 122 out of 241 residues of PfCP-2.9. The assigned
residues in PfCP-2.9 were very similar to those previously reported for the individual domains. The conformation of
the PfMSP1-19 in different constructs is essentially the same. Comparison of transverse relaxation rates (R2) strongly
suggests no weak interaction between the domains.
Conclusions: These data indicate that the fusion of AMA-1(III) and MSP1-19 as chimeric protein did not change
their structures, supporting the use of the chimeric protein as a potential malaria vaccine.
Background
Malaria is one of the most serious life-threatening tropi-
cal diseases in the world. Because of the rapid spread of
drug-resistant parasites and insecticide-resistant mosqui-
toes [1-4], new tools for control malaria are urgently
needed. The 200-kDa merozoite surface protein-1 (MSP
1) and the apical membrane antigen (AMA-1) of Plas-
modium falciparum are attractive candidates for malaria
vaccines [5-9]. These two antigens are located on the
merozoite surface and have been proposed to play a role
in the invasion process [10-15]. A portion of the MSP1
targeted by protective immunity antigen has been
mapped to the 19 kDa carboxy-terminal region (MSP1-
19) which contains two tandem repeat epidermal growth
factor (EGF)-like domains while the most C-terminal of
the disulphide-bonded domains in AMA-1 (Domain III)
was also a target for inhibitory antibodies isolated from
malaria patients [16-20].
A chimeric protein (PfCP-2.9) was constructed com-
prising the sequences of both AMA-1(III) and the MSP
1-19 from P. falciparum [21]. The two proteins were
fused via a hinge encoding a Gly-Pro-Gly motif repeat,
and a secreted form of the PfCP-2.9 protein was
expressed in Pichia pastoris. The fusion enhanced pro-
duct yield, immunogenicity, and antibody-mediated inhi-
bition of parasite growth in vitro. Sera from rabbits and
rhesus monkeys immunized with the chimeric antigen
almost completely inhibited parasite growth. Two phase
I clinical trials of this vaccine candidate formulated in
Montanide ISA 720 were completed recently, demon-
strating the safety, tolerability, and immunogenicity of
the vaccine in humans [22,23].
The PfCP-2.9 chimeric protein contains 18 cysteine
residues, six of which are located in AMA-1(III) region
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intramolecular disulfide bonds. Protective immunity
conferred by this vaccine candidate was shown to be
dependent on its disulfide backbone-based conforma-
tion. Immune sera containing reduced and alkylated
PfCP-2.9 did not inhibit parasite growth, indicating that
induction of the growth-inhibitory response required
proper folding of this chimeric protein [21]. Therefore,
it is necessary to characterize the structure of the fusion
protein. In the present study, the
15N- and
15N/
13C-
labeled PfCP-2.9 protein were expressed in P. pastoris to
determine its solution structure.
Methods
Reagents
15NH4SO4 and
13C-D-glucose was purchased from Cam-
bridge Isotope Laboratories (Andover, MA, USA).
13C-
methanol was purchased from Spetra (Columbia, MD,
USA).
Preparation of
15N-labeled PfCP-2.9
The stock P. pastoris strain [21] expressing PfCP-2.9
with C-terminal 6 × His tags was streaked on a YPD
agar plate (1% Yeast extract, 2% Peptone, 2% Glucose,
2% agar) containing the antibiotic G418 (0.25 mg/ml).
Clones were incubated in 150 ml BMGY medium
(1.34% yeast nitrogen base [YNB] without ammonium
sulfate and amino acids, 1% yeast extract, 2% peptone,
1% glycerol, 4 × 10
-5% biotin, and 100 mM potassium
phosphate [pH 6.0]) and grown to an optical density of
approximately 20 at 600 nm (OD600). The cells were
then transferred into 3L of
15N salt base medium (2.67%
[v/v] H3PO4 (85%), 0.0894% CaSO4, 1.52% K2SO4, 1.49%
MgSO4·7 H 2O, 0.413% KOH, 4% glycerol, 0.4% [v/v]
PTM1 salts, 0.9% [NH4]2SO4) in a 5-L fermenter. OD600
reached 75 after 21 hr, and 180 g methanol was then
added to induce expression of the chimeric protein.
After 19 hr, the culture was centrifuged at 6000 × g for
20 min at 4°C, and the supernatant was collected for
protein purification.
The target protein was purified by Ni-NTA agarose
column (Qiagen, Hilden, Germany) affinity purifica-
tion. Ten milliliters of Ni-NTA agarose was equili-
brated with the loading buffer (50 mM NaH2PO4, 300
m MN a C l ,p H8 . 0 )w i t h o u tar e d u c i n ga g e n t .T h ec e l l
culture supernatant was then applied to the column at
1 ml/min, and flow through was collected for analysis.
The column was washed with 60 ml loading buffer fol-
lowed by 120 ml washing buffer (50 mM NaH2PO4,
300 mM NaCl, 20 mM imidazole, pH 8.0). Bound pro-
teins were eluted with 250 mM imidazole. Eluted pro-
teins were concentrated into 1 ml using an Amicon
Ultra-15 centrifugal filter unit (10 kDa, Millipore, Bill-
erica, USA).
The NMR sample was prepared in a buffer containing
20 mM sodium phosphate in 90% H2O/10% D2O (pH
7.4). The sample was argon-flushed.
Preparation of
13C/
15N-labeled PfCP-2.9
The stock P. pastoris strain was streaked on a YPD agar
p l a t ea n dg r o w ni n3Lo f
15N salt base as described
above. The cell density reached OD600 of 60 after 17 hr,
and 5 g of
13C-D-glucose was then added. After 2 hr, 50
go f
13C-methanol was added to induce chimeric protein
expression. After 6 hr, the culture was centrifuged at
6,000 × g for 20 min at 4°C, and the supernatant was
collected for protein purification.
The purification and NMR sample preparation of the
target protein was same as for
15N-labeled PfCP-2.9.
The final volume was 1.2 ml. Protein concentration was
10 mg/ml as determined by the Bradford method, and
purity was > 90% as assessed by SDS-PAGE.
Preparation of
15N-labeled PfMSP1-19
The stock P. pastoris strain was streaked on a YPD agar
plate containing 0.25 mg/ml G418, which was preserved
in laboratory. A clone was incubated in 500 ml BAGY
medium (0.34% YNB without ammonium sulfate and
amino acids, 1% glycerol, 0.5% (NH4)2SO4,4×1 0
-5%
biotin, and 100 mM potassium phosphate [pH 6.0]) and
grown to OD600 of approximately 10. Cells were col-
lected by centrifugation and transferred into 500 ml of
15N BMM medium (0.34% YNB without ammonium
sulfate and amino acids, 0.5% methanol, 0.5% (NH4)
2SO4,4×1 0
-5% biotin, and 100 mM potassium phos-
phate [pH 6.0]). Every 12 hr, 1.25 ml of methanol was
added to the culture medium. After 72 hr, the culture
was centrifuged at 6,000 × g for 20 min at 4°C to collect
the supernatant for protein purification. The purification
process and NMR sample preparation was the same as
for PfCP-2.9.
Nuclear magnetic resonance data collection and analysis
The nuclear magnetic resonance (NMR) spectra were
acquired at 25°C with a Bruker Avance 500 (with a
CryoProbe) and 800 MHz spectrometers, equipped with
four RF channels and a triple-resonance probe with
pulsed field gradients. The three-dimensional (3D)
HNCA, HNCACB, CBCA(CO)NH, HNCO, and HN
(CA)CO experiments were carried out for the backbone
assignments. HBHA(CO)NH, (H)CC(CO) NH, CC(CO)
NH, and
15N-TOCSY-HSQC experiments were per-
formed for side-chain assignments [24]. 3D
15N-edited
NOESY-HSQC spectrum (mixing time, 100 ms) was
performed to confirm the chemical shift assignments.
All spectra were processed using the software package
NMRPipe [25] and analysed with the programme
NMRView [26].
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15N transverse relaxation measurements
The backbone
15N transverse relaxation experiments of
the PfCP-2.9 and MSP 1-19 domain were recorded [27]
on a Bruker AVANCE 800-MHz NMR spectrometer at
25°C. For both samples, 512 (
1H) and 70 (
15N) complex
data points were collected with 48 transients per incre-
ment and a recycle delay of 3.0 s. The delays were 4 (×2),
32, 60, 100, 160 ms for
15N-labeled MSP 1-19, and 4 (×2),
12, 28, 48, 72, 100, 160 ms for
15N-labeled PfCP-2.9. The
transverse relaxation rate constants (R2) were obtained by
fitting the peak intensities to a single exponential function
by nonlinear least-squares method using MATLAB [28].
Results
Chemical shift assignments of PfCP-2.9
The chemical shift assignments of PfCP-2.9 were per-
formed based on the triple-resonance NMR spectra
aided by the previously reported NMR assignments for
the PfAMA-1(III) domain (Biological Magnetic Reso-
nance Data Bank [BMRB] entry 4787) and PfMSP1-19
domain (BMRB entry 4437) [29,30]. Backbone assign-
ments were obtained for 39 out of 116 residues of the
PfAMA-1(III) domain, 12 out of 28 residues of the
hinge region, and 71 out of 97 residues of the PfMSP1-
19 domain. Side-chain chemical shifts were also partially
obtained. As shown in the 2D
15N-edited heteronuclear
single quantum coherence (HSQC) spectrum of PfCP-
2.9 (Figure 1), most of the well-dispersed peaks were
assigned. The residues that could not be unambiguously
assigned were clustered in the central region of the
spectrum due to severe overlap. For the PfAMA-1(III)
domain, the residues with assigned backbone amides
and C
a and/or C
b atoms were Leu16-Asp19, Ser29-
Arg31, Gly42-Lys44, Ile46-Ala47, Ser53-Asp55, Asp57-
Leu59, Cys63, Val68, Ser71, Phe76-Cys78, Ala85-Val87,
Ser89, Val94-Lys96, Tyr103-Ile106, and Thr112-Tyr113.
Additional chemical shift assignments of the C
a and/or
C
b atoms (and in most cases H
a and H
b atoms) were
obtained for residues Ser15, Lys56, Phe75, Thr88,
Glu102, and Pro111. The mapping of these assigned
residues onto the NMR structure of the PfAMA-1(III)
domain (PDB code 1HN6) is shown in Figure 2, which
indicates that the assigned residues are spread over
different regions of this domain, including both
Figure 1 The 2D
15N-edited HSQC spectrum showing the backbone assignments of PfCP-2.9. The assigned backbone amides of PfCP-2.9
are labeled with the one-letter amino acid codes and are numbered according to the sequence of PfCP-2.9. The residue G234 (labeled in red) is
folded in the spectrum.
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many residues in the core structural region were
assigned.
For the PfMSP1-19 domain, the residues with assigned
backbone amides as well as C
a and/or C
b atoms are
His150-Cys152, Lys154, Asn160-Arg165, Asp168-
Glu171, Leu176-Asn189, Gln191, Thr193-Glu196,
Asn198-Lys225, Asp227-Tyr229, and Phe232-Ser238.
Additional chemical shift assignments of the C
a and C
b
atoms (and in most cases H
a and H
b atoms) can be
obtained for residues Gln149, Val153, Gln159, Leu167,
Pro190, Pro192, Asn197, Pro226, and Leu231. The map-
ping of these assigned residues onto the NMR structure
of the MSP 1-19 domain (PDB code 1CEJ) is displayed
in Figure 3, which shows that the majority of the resi-
dues in this domain were assigned.
Comparison of the assigned chemical shifts of PfCP-2.9
with those of PfAMA-1 (III) and Pf MSP1-19 domains
As shown in Figure 4, nearly all of the assigned residues
in PfCP-2.9 display chemical shifts highly similar to
those reported for the individual domains PfAMA-1(III)
and PfMSP1-19 [29,30]. For the residues assigned in
PfAMA-1 III domain, the majority show the following
chemical shift differences: |ΔH
N| < 0.2 ppm, |ΔN| < 1.5
ppm, |ΔC
a| < 1.0 ppm, |ΔC
b| < 1.5 ppm, and |ΔCO| <
1.0 ppm. Only a few atoms show relatively large chemi-
cal shift differences between the present results and pre-
viously published assignments of AMA1 III (BMRB
entry 4787) [29]. These include the H
N atoms of Lys43
and Lys79, the backbone
15Na t o mo fL y s 4 3 ,t h eC a
atom of Asp105, and the Cb atoms of Cys63 and
Asp105. The difference might be due to the fact that in
the NMR study of AMA1 III domain alone was per-
formed using refolded protein under acidic (pH 3.4) buf-
fer condition [29], while in the present study neutral
(pH 7.4) buffer condition was used.
For the residues assigned in the PfMSP1-19 domain,
the majority show only small chemical shift differences:
|ΔH
N| < 0.1 ppm, |ΔN| < 1.0 ppm, |ΔCa| < 0.5 ppm,
|ΔCb| < 1.0 ppm, |ΔCO| < 0.5 ppm. Few atoms show
bigger chemical shift differences between the current
results and previously published assignments of
PfMSP1-19 (BMRB entry 4437) [30]; these include the
Figure 2 Mapping of the assigned residues onto the AMA1
domain III structure. The residues with assigned backbone amides
are blue. The proline residues (which have no amides) and residues
without backbone assignments but with C
a and C
b atoms that
could be assigned are green. The disulfide bridges are shown, and
the cysteine residues are labeled. The residues are numbered
according to the sequence of PfCP-2.9. The structure corresponds to
the first conformer of the NMR structures of AMA1 domain III (PDB
code 1HN6). The figure was generated by MOLMOL.
Figure 3 Mapping of the assigned residues onto the MSP1-19
domain structure. The residues with assigned backbone amides
are blue. The proline residues (which have no amides) or residues
without backbone assignments but with C
a and C
b atoms that
could be assigned are green. The disulfide bridges are shown, and
the cysteine residues are labeled. The residues are numbered
according to the sequence of PfCP-2.9. The structure corresponds to
the first conformer of the NMR structures of MSP 1-19 domain (PDB
code 1CEJ). The figure was generated by MOLMOL.
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Page 4 of 9Figure 4 Chemical shift comparison between PfCP-2.9 and the individual AMA1 III and MSP 1-19 domains. (A) Chemical shift differences
for the H
N,N ,C
a,C
b, and CO atoms between the AMA1 III domain in PfCP-2.9 and the AMA1 III domain alone (BMRB entry 4787). (B) Chemical
shift differences for the H
N,N ,C
a,C
b, and CO atoms between the MSP 1-19 domain in PfCP-2.9 and the MSP 1-19 domain alone (BMRB entry
4437). The residues are numbered according to the sequence of PfCP-2.9. The figure was generated by Origin 8.0.
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15N atoms of Glu169, Glu171 and Ala203, and
the Ca atom of Ser238. The Glu169 and Glu171 resi-
dues are acidic residues, whereas the Ala203 residues
are located between two Asp residues. The larger
15N
chemical shift differences for these three residues prob-
ably result from the pH differences of buffers used in
the two studies (buffer pH used in the previous study of
the PfMSP1-19 domain was 6.5).
Spectral comparison between PfCP-2.9 and MSP 1-19
domain
To provide further evidence that the structures of the
two domains remain unchanged in the chimeric protein
PfCP-2.9, the PfAMA-1(III) and PfMSP1-19 domains
were expressed separately in P. pastoris and dissolved in
the same buffer as PfCP-2.9. Unfortunately, the
15N-edi-
ted HSQC spectrum of the
15N-labeled PfAMA-1(III)
domain indicated that the separately expressed protein
domain was not properly folded; however, the
15N-edi-
ted HSQC spectrum of
15N-labeled PfMSP1-19 domain
showed well-dispersed peaks, demonstrating the protein
had folded well. The overlay of the HSQC spectra of
PfMSP1-19 and PfCP-2.9 (Figure 5) demonstrated that
the structure of the PfMSP1-19 domain in PfCP-2.9 is
the same as PfMSP1-19 expressed alone. The chemical
shift differences (Figure 6) were within experimental
errors for all peaks, with the exception of His150 and
Ser238. His150 is preceded by the linker sequence in
PfCP-2.9, whereas it is close to the N-terminus in
PfMSP1-19. The residue Ser238 is close to the C-termi-
nus of both proteins and could be easily affected by
slight condition differences between samples (e.g., differ-
ences in purity). Moreover, no any signal disappearance
was observed by comparing the two spectra. These data
strongly demonstrated that the conformation of
PfMSP1-19 domain in the fusion protein is identical to
PfMSP1-19 domain alone.
Comparison of transverse relaxation rates between PfCP-
2.9 and PfMSP1-19 domain
The lack of change in chemical shifts of the PfMSP1-19
domain when expressed as a part of the fusion protein
PfCP-2.9 excludes the possibility of strong interactions
between PfMSP1-19 and PfAMA-1(III) domains; how-
ever, weak interactions between the two domains are
possible. If weak interactions between the two domains
exist, one or both of the following phenomena were
expected to seen: (1) chemical shift differences for
Figure 5 Overlay of 2D
15N-edited HSQC spectra of PfCP-2.9 and MSP 1-19. The spectrum of PfCP-2.9 is shown in black and spectrum of
MSP 1-19 alone is shown in red.
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due to chemical/conformational changes.
Neither chemical shift changes between the two spectra
nor peak disappearance was observed; therefore, the
transverse relaxation rates R2 of the two samples were
measured to further investigate the possibility of line
broadenings. For the data analysis of PfCP-2.9, only those
residues present in PfMSP1-19 were analysed. The peaks
that overlapped were excluded from the analysis. Further,
residues His150, Glu171, Asp184, Gly213, Ser228, and
Ser238 showed weak signals and poor relaxation curves
in both samples, thus were also removed from the final
analysis. The R2 values of a total of 36 residues (Cys152,
Asn160-Gly162, Phe164, Asp168-Glu169, Leu177-
Lys180, Cys186-Glu188, Asn191, Thr193-Glu196,
Gly199-Gly200, Ala203-Asp204, Lys206-Thr208, Gly216,
Ile219-Thr220, Cys223-Thr224, Asp227, and Asp233-
Phe236) were finally obtained.
The R2 values of these residues were compared
between PfCP-2.9 and PfMSP1-19. The R2 values were
overall higher for residues in PfCP-2.9 compared with
those in PfMSP1-19, which is due to the higher molecu-
lar weight and slower molecular tumbling of PfCP-2.9.
By overlaying the two datasets (Figure 7), the trend of
R2 values over residue number is essentially the same
for the two samples. No significant increase of trans-
verse relaxation rates were observed for any region. This
result indicates that no residue chemical/conformational
changes occurred in the PfMSP1-19 domain of PfCP-
2.9, suggesting that the PfMSP1-19 domain is not likely
to be involved in weak interactions with the AMA-1(III)
domain or the linker region.
Discussion
It has been reported that a panel of monoclonal antibo-
dies recognizing conformational epitopes on PfMSP1-19
interacted with the chimeric protein with reduced sensi-
tivity [21]. Of these monoclonal antibodies, mAb2.2 and
12.8 bind to the first EGF domain of PfMSP1-19,
whereas mAb111.2 requires the presence of both EGF-
like domains [31]. The mAb12.8 is an inhibitory
antibody while mAb 2.2 and mAb 1E1 are blocking anti-
bodies [32,33]. These data indicated that the critical epi-
topes were retained after fusion of the two domains into
one molecule; however, correct folding of the PfAMA-1
(III) portion and other epitopes on the PfMSP1-19 and
potential interactions between the two domains was not
known.
Figure 6 Chemical shift comparison between PfCP-2.9 and MSP 1-19. Chemical shift differences of backbone H
N atoms (upper panel) and N
atoms (lower panel) between MSP 1-19 and PfCP-2.9 are shown. The chemical shift differences were calculated by subtracting the chemical shift
values for each residue in the MSP 1-19 domain in PfCP-2.9 from those in MSP 1-19 alone. The residues are numbered according to the
sequence of PfCP-2.9. The figure was generated by Xmgrace.
Figure 7 Comparison of transverse relaxation rates (R2) between PfCP-2.9 and MSP 1-19. Overlay of the R2 values of MSP 1-19 (red stars)
alone and the MSP 1-19 domain in PfCP-2.9 (black circles). The scale of the R2 values for PfCP-2.9 is on the left, and the scale for MSP 1-19 is on
the right. The residues are numbered according to the sequence of PfCP-2.9. The figure was generated by Xmgrace.
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PfCP-2.9 was compared with those previously reported
for individual domains and found that the structures of
the two domains were unchanged. Further, comparison
of the 2D spectra of PfMSP1-19 with the domain in the
PfCP-2.9 also demonstrated that the conformation of
the domain is essentially the same, while the PfAMA-1
(III) domain showed better folding in the chimeric pro-
tein than it did alone.
Comparison of transverse relaxation rates R2 between
the PfMSP1-19 domain in PfCP-2.9 and the domain
a l o n es t r o n g l ys u g g e s t sn ow eak interactions between
domains. Taken together, these data suggested that the
structures of the PfAMA-1(III) and PfMSP1-19 domains
were not altered by fusion into the chimeric protein.
Crystallization the chimeric protein were unsuccess-
ful despite various efforts. Therefore,
15N-labeled and
13C/
15N-labeled PfCP-2.9 were expressed in P. pastoris
for NMR structure analysis. The backbone chemical
shift assignments can be obtained for a reasonable por-
tion of the residues in PfCP-2.9. By comparing with
the previously reported studies of the two domains
alone, high similarity of chemical shifts was observed.
Relatively larger differences were observed for only a
small number of residues, which may be due to differ-
ent experimental conditions (e.g., buffer pH and tem-
perature). In fact, almost all the residues that showed
significant chemical shift changes in PfAMA-1(III)
were charged residues, with the exception of Cys63,
which is near charged residues according to the NMR
structure of PfAMA-1 (III). In addition, PfCP-2.9 was
modified in the following ways: three glycosylation
sites were removed by changing Asn to Gln, a hinge
consisting of 28 residues was inserted between the two
domains [21], and a 6×His-tag was added to its C-ter-
minus. These modifications can also influence the che-
mical shift of nearby residues.
The PfCP-2.9 chimeric protein induces antibodies that
inhibit parasite growth in vitro, providing additional evi-
dence for the unchanged protein conformation. More-
over, both components of the chimeric protein are able
to generate inhibitory antibodies against parasite growth,
indicating that both domains fold correctly [21]. NMR
findings in the present studyw e r ec o n s i s t e n tw i t hp r e -
vious reports. The lack of interaction between the two
domains greatly reduces the possibility that novel epi-
topes exist in the chimeric protein.
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